PERFOCTAPS: Studying the Performance of OCT C-scan in the Screening for Retinopathy Related to Synthetic Antimalarials

Sponsor
Fondation Ophtalmologique Adolphe de Rothschild (Other)
Overall Status
Completed
CT.gov ID
NCT02719002
Collaborator
(none)
109
1
1
56.6
1.9

Study Details

Study Description

Brief Summary

Maculopathy induced by retinal toxicity of synthetic antimalarials is to be screened at the sub-clinical stage. Indeed, when the first visual symptoms appear, macular damage is already irreversible and the clinical picture may even continue to deteriorate for several years after the end of synthetic antimalarial use. In opposition, the early termination of hydroxychloroquine in patients showing recent alterations on the multifocal electroretinogram (nfERG) allowed he reversibility of toxic damage over a six month period. It is therefore critical to detect early retinal anatomic changes during retinotoxicity screening before the occurrence of irreversible anatomical and functional consequences.

The usual patient monitoring consists of an annual eye examination, detecting subjective functional abnormalities (visual acuity, color vision, central visual field testing) or macular lesions (eye fundus). These abnormalities show a constituted infringement and do not contribute to the early diagnosis of synthetic antimalarial maculopathy.

The mfERG is an objective examination, able to detect retinal damage whilst still reversible. It is recommended during the annual monitoring and is, today, the gold standard for the screening and diagnosis of synthetic antimalarial maculopathy. However, its realization is time consuming, requires a good patient cooperation and is difficult to access due to the few ophthalmology centers offering it. In practice, it is rarely done as a systematic annual screening for patients on long-term synthetic antimalarial treatment. It is often limited to second-line studies (for patients already showing functional or anatomical abnormalities) whereas its interest lies in the detection of early lesions.

The Optical Coherence Tomography Spectral Domain (OCT-SD) is a non-invasive eye examination, commonly used since nearly 10 years. A special image analysis provides a panoramic viewing of the state of the photoreceptor layer, and a non-invasive detection of any anatomical changes, even subtle, within this layer.

The concordance between the "en face" OCT and the mfERG in the screening of synthetic antimalarial maculopathy is considered in this study.

Condition or Disease Intervention/Treatment Phase
  • Device: spectral domain optical coherence tomography C-scan and multifocal electroretinogram
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
109 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Studying the Performance of OCT C-scan in the Screening for Retinopathy Related to Synthetic Antimalarials
Actual Study Start Date :
Aug 26, 2016
Actual Primary Completion Date :
Feb 18, 2021
Actual Study Completion Date :
May 15, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: OCT C-scan

Device: spectral domain optical coherence tomography C-scan and multifocal electroretinogram

Outcome Measures

Primary Outcome Measures

  1. concordance between mfERG and SD OCT C-scan [2 years]

    measure of kappa coefficient

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients treated with synthetic antimalarials for at least 5 years
Exclusion Criteria:
  • state of ocular structures preventing the realization of exams

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fondation Ophtalmique Adolphe de Rothschild Paris France 75019

Sponsors and Collaborators

  • Fondation Ophtalmologique Adolphe de Rothschild

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fondation Ophtalmologique Adolphe de Rothschild
ClinicalTrials.gov Identifier:
NCT02719002
Other Study ID Numbers:
  • MMT_2015_45
First Posted:
Mar 24, 2016
Last Update Posted:
Jan 10, 2022
Last Verified:
Dec 1, 2021

Study Results

No Results Posted as of Jan 10, 2022